.png){kind=icon}
L
Lieping Chen
H指数:131
被引数:9.4万
个人简介
My research focuses on identifying novel cell surface and secreted proteins that govern T cell activation, tolerance, memory, and survival. My career is also dedicated to translating fundamental laboratory discoveries into transformative therapies, primarily in cancer immunotherapy. In 1992, my laboratory published the first proof-of-concept study demonstrating that manipulating the B7-CD28 family, specifically by introducing B7-1 into tumor cells, could enhance anti-tumor immunity. In 1999, my laboratory discovered the B7-H1 (PD-L1) molecule and was the first to establish the PD-1/PD-L1 pathway as a mechanism of immune evasion within the tumor microenvironment (TME). These foundational findings led me to co-initiate the first-in-human clinical trial of PD-1/PD-L1 blockade in 2006. We further pioneered the use of PD-L1 tumor tissue staining as a predictive biomarker, a contribution that directly informed the FDA approval of anti-PD-1/PD-L1 antibodies and redefined the standard of care across multiple cancers. My central hypothesis, that the TME is the primary site of immune evasion, remains a cornerstone of contemporary tumor profiling and drug discovery. Beyond the PD-1/PD-L1 axis, my laboratory has identified over 20 novel immune modulators, including 4-1BB, ICOS/B7-H2, B7-H3, B7-H4, B7-H5/CD28H, PD-1H, LIGHT/HVEM, FGL1/LAG-3, Siglec-15, CD93/IGFBP7, and CD8a/PILRa. By discovering their mechanisms of action and therapeutic potential, we have catalyzed broad therapeutic development programs across academia and industry. Several of these targets are now in advanced clinical stages: 4-1BB agonists and B7-H4 antibodies are in Phase I/II trials; B7-H3 is a target for ADCs, bispecific T cell engagers, and CAR-T therapies (Phase I-III); and Siglec-15 and CD93 antibodies have reached Phase II.
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
Siglec-15和PD-1检查点阻断与溶瘤寨卡病毒感染联合应用可对抗免疫抵抗性胶质瘤
Neuro-Oncology
IF13.4
靶向B7-H3的CAR-T细胞颅内递送治疗复发性胶质母细胞瘤：一项1期临床试验
Nature Medicine
IF50
联合使用Siglec-15和PD-1的双阻断疗法，结合溶瘤寨卡病毒疗法，能够对抗免疫抵抗性胶质瘤的保护作用。
NEURO-ONCOLOGY
IF13.4
NSCLC中不断发展的免疫血管生成范式: ivonescimab的经验教训
PD-L1与现代癌症免疫治疗的黎明
NATURE MEDICINE
IF50
空间转录组学揭示盘状红斑狼疮和扁平苔藓中差异炎症通路
PD-1H (VISTA)在皮肤鳞状细胞癌中的表达与T细胞浸润和活化相关
脂质代谢在癌症研究和治疗中有价值吗？第一部分-癌症中的脂质代谢
METABOLITES
IF3.7
METABOLITES
IF3.7
SCIENCE IMMUNOLOGY
IF16.3
Anti-Siglec-15抗体预防急性脊髓损伤诱导的大鼠固定后明显的骨丢失
JBMR PLUS
IF2.4
HUMAN IMMUNOLOGY
IF2.2
SCIENTIFIC REPORTS
IF3.9
